Of note, by targeting the IL-17 receptor A (IL-17RA) through selective binding to homodimers or heterodimers, drugs such as bimekizumab and secukinumab block downstream signalling and inhibit the inflammatory pathway; they have proven efficacy in treating HS, further expanding the frontiers in HS management and providing a rationale for targeting IL-17 in HS [11]. Here, IL17A is linked to histiocytic sarcoma.